M. Chan, R. Kefford, and M. Carlino, Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic Melanoma, Journal of Immunotherapy, vol.38, issue.1, pp.37-46
DOI : 10.1097/CJI.0000000000000060

A. Patnaik, S. Kang, and D. Rasco, Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res, pp.4286-93, 2015.

S. Topalian, F. Hodi, and J. Brahmer, Safety, Activity, and Immune Correlates of Anti???PD-1 Antibody in Cancer, New England Journal of Medicine, vol.366, issue.26, pp.2443-54, 2012.
DOI : 10.1056/NEJMoa1200690

J. Westin, F. Chu, and M. Zhang, Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial, The Lancet Oncology, vol.15, issue.1, pp.69-77, 2014.
DOI : 10.1016/S1470-2045(13)70551-5

S. Topalian, C. Drake, and D. Pardoll, Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy, Cancer Cell, vol.27, issue.4, pp.450-61, 2015.
DOI : 10.1016/j.ccell.2015.03.001

M. Van-der-vlist, J. Kuball, and T. Radstake, Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?, Nature Reviews Rheumatology, vol.8, issue.10, pp.593-604, 2016.
DOI : 10.1093/intimm/8.5.765

D. Chen, B. Irving, and F. Hodi, Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1, Clinical Cancer Research, vol.18, issue.24, pp.6580-6587, 2012.
DOI : 10.1158/1078-0432.CCR-12-1362

URL : http://clincancerres.aacrjournals.org/content/clincanres/18/24/6580.full.pdf

C. Granier, S. Karaki, and H. Roussel, Cancer immunotherapy: Rational and recent breakthroughs], Rev Med Interne, vol.pii, issue.16, pp.248-866330413, 2016.

L. Cappelli, A. Gutierrez, and C. Bingham, Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature, Arthritis Care & Research, vol.34, issue.11, 2016.
DOI : 10.1200/JCO.2009.26.7609

M. Bilen, S. Subudhi, and J. Gao, Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody, Journal for ImmunoTherapy of Cancer, vol.2, issue.1, p.36, 2016.
DOI : 10.1158/2326-6066.CIR-13-0146

J. Salmon, I. Lambrecht, and P. Brochot, A case of arthritis under pembrolizumab, Joint Bone Spine, vol.84, issue.2, pp.243-244, 2017.
DOI : 10.1016/j.jbspin.2016.03.003

T. Kimura, S. Fukushima, and A. Miyashita, Myasthenic crisis and polymyositis induced by one dose of nivolumab, Cancer Sci, pp.1055-1063, 2016.

L. Cappelli, A. Gutierrez, and A. Baer, Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab, Annals of the Rheumatic Diseases, vol.34, issue.1, pp.43-50, 2017.
DOI : 10.1007/s10620-016-4042-4

C. Calabrese, E. Kirchner, and K. Kontzias, Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment, Ann Rheum Dis, vol.3, issue.1, pp.412-428, 2009.

E. Eisenhauer, P. Therasse, and J. Bogaerts, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-275, 2009.
DOI : 10.1016/j.ejca.2008.10.026

C. Naranjo, U. Busto, and E. Sellers, A method for estimating the probability of adverse drug reactions, Clinical Pharmacology and Therapeutics, vol.30, issue.2, pp.239-284, 1981.
DOI : 10.1038/clpt.1981.154

J. Bonigen, C. Raynaud-donzel, and J. Hureaux, Anti-PD1-induced psoriasis: a study of 21 patients, Journal of the European Academy of Dermatology and Venereology, vol.107, issue.5, 2016.
DOI : 10.1016/j.ad.2015.07.012

L. Zimmer, S. Goldinger, and L. Hofmann, Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy, European Journal of Cancer, vol.60, pp.210-235
DOI : 10.1016/j.ejca.2016.02.024

B. Garel, N. Kramkimel, and A. Trouvin, Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma, Joint Bone Spine, vol.84, issue.2, pp.233-234, 2017.
DOI : 10.1016/j.jbspin.2016.01.007

L. Burel, S. Champiat, S. Mateus, and C. , Prevalence of immune-related systemic adverse events in??patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis, European Journal of Cancer, vol.82, pp.34-44, 2017.
DOI : 10.1016/j.ejca.2017.05.032

L. Spain, S. Diem, and J. Larkin, Management of toxicities of immune checkpoint inhibitors, Cancer Treatment Reviews, vol.44, pp.51-60
DOI : 10.1016/j.ctrv.2016.02.001

C. Boutros, A. Tarhini, and E. Routier, Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination, Nature Reviews Clinical Oncology, vol.33, issue.8, pp.473-86, 2016.
DOI : 10.1001/jamadermatol.2015.2707

A. Bertrand, M. Kostine, and T. Barnetche, Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor, BMC Med Immunity, vol.1311, issue.2, pp.211-26141, 1999.

E. Tivol, F. Borriello, and A. Schweitzer, Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4, Immunity, vol.3, issue.5, 1995.
DOI : 10.1016/1074-7613(95)90125-6

H. Kuehn, W. Ouyang, and B. Lo, Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4, Science, vol.37, issue.12, pp.1623-1627, 2014.
DOI : 10.1002/gepi.21743

B. Vaidya, S. Pearce, and S. Charlton, An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies, Rheumatology, vol.41, issue.2, pp.180-183, 2002.
DOI : 10.1093/rheumatology/41.2.180

Y. Lee, S. Bae, and J. Kim, Meta-analysis of genetic polymorphisms in programmed cell death 1. Associations with rheumatoid arthritis, ankylosing spondylitis, and type 1 diabetes susceptibility, Z Rheumatol. 2015, vol.74, issue.3, pp.230-239

H. Zhang, R. Watanabe, and G. Berry, Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis, Proceedings of the National Academy of Sciences, vol.66, issue.3, 2017.
DOI : 10.1084/jem.20150900

M. Freeman-keller, Y. Kim, and H. Cronin, Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes, Clinical Cancer Research, vol.22, issue.4, pp.886-94, 2016.
DOI : 10.1158/1078-0432.CCR-15-1136

T. Horvat, N. Adel, and T. Dang, Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center, Journal of Clinical Oncology, vol.33, issue.28, pp.3193-3201, 2015.
DOI : 10.1200/JCO.2015.60.8448